Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against gram-positive bacteria, in a neutropenic murine thigh model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1578-1583

  Hegde, Sharath S ^a   Okusanya, Olanrewaju O ^b   Skinner, Robert ^a   Shaw, Jeng Pyng ^a   Obedencio, Glenmar ^a,c   Ambrose, Paul G ^b   Blais, Johanne ^a   Bhavnani, Sujata M ^b  

^a THERAVANCE INC   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c BioDuro   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; HETERODIMER; METICILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; TD 1792; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPEPTIDES; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THIGH; VANCOMYCIN;

EID: 84857171002     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05382-11     Document Type: Article

References (18)

1. Akaike H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242. (Pubitemid 9228573)
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
3. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268. (Pubitemid 34308974)
4. Bauer RJ. 2006. S-ADAPT/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Los Angeles, CA. http://bmsr.usc.edu/Software/ADAPT/SADAPTsoftware.html.
5. Bhavnani et al. 2011. Abstr. 51th Intersci. Conf. Antimicrob. Agents Chemother., abstr A2-044. Chicago, IL, 16 to 20 September 2011. http: //www.icaac.org/.
6. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-eighth edition. CLSI document M7-A8. CLSI, Wayne, PA.
7. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501. (Pubitemid 38029149)
8. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. (Pubitemid 28068148)
9. Deresinski S. 2007. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev. Anti Infect. Ther. 5:393-401. (Pubitemid 47050161)
10. Difuntorum S, et al. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2007, abstr F1-2110. American Society for Microbiology, Washington, DC.
11. Drusano GL. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297. (Pubitemid 18063550)
12. Hegde SS, et al. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050. (Pubitemid 38989173)
13. Krause K, et al. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2007, abstr E-1626. American Society for Microbiology, Washington, DC.
14. Long DD, et al. 2009. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers. J. Antibiot. (Tokyo) 61:603-614.
15. Lunde C, et al. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-1344. American Society for Microbiology, Washington, DC.
16. Nailor MD, Sobel JD. 2009. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect. Dis. Clin. North Am. 23:965-982.
17. Stryjewski et al. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2007, abstr L-1147a. American Society for Microbiology, Washington, DC.
18. Woodford N, Livermore DM. 2009. Infections caused by Gram-positive bacteria: a review of the global challenge. J. Infect. 59(Suppl. 1):S4-S16.